Tuftsin-tailored fusion protein inhibits the growth of circulating gastric tumor cells associated with macrophage phagocytosis

[1]  Rachel E. Brewer,et al.  Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication , 2022, Nature Medicine.

[2]  E. Buchbinder,et al.  Cancer Therapy Targeting CD47/SIRPα , 2021, Cancers.

[3]  K. Kaur,et al.  Peptide-Drug Conjugates with Different Linkers for Cancer Therapy. , 2020, Journal of medicinal chemistry.

[4]  W. Haq,et al.  Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice , 2020, International journal of nanomedicine.

[5]  M. Khan.  Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the treatment of infectious diseases and tumors. , 2020, Current drug targets.

[6]  Qing Yang,et al.  Tumor‐associated macrophage‐targeted therapeutics in ovarian cancer , 2020, International journal of cancer.

[7]  D. Teng,et al.  Treatment Effect of Tuftsin and Antigen Peptide Combined with Immune Cells on Colorectal Cancer , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[8]  Y. Zhen,et al.  Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. , 2019, Cancer letters.

[9]  K. Abbaszadeh-Goudarzi,et al.  Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes , 2018, Journal of cellular physiology.

[10]  I. Weissman,et al.  CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma , 2018, The New England journal of medicine.

[11]  Jia‐Lin Wang,et al.  Enediyne-activated, EGFR-targeted human β-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma , 2018, Laboratory Investigation.

[12]  Y. Zhen,et al.  EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis , 2018, Acta Pharmacologica Sinica.

[13]  S. Tsirka,et al.  Tuftsin‐driven experimental autoimmune encephalomyelitis recovery requires neuropilin‐1 , 2016, Glia.

[14]  I. Weissman,et al.  First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Fabao Gao,et al.  Isolation and characterization of circulating tumor cells from human gastric cancer patients , 2015, Journal of Cancer Research and Clinical Oncology.

[16]  Ming Liu,et al.  P-Akt/miR‑200 signaling regulates epithelial-mesenchymal transition, migration and invasion in circulating gastric tumor cells. , 2014, International journal of oncology.

[17]  Y. Zhen,et al.  Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation , 2014, Cancer Immunology, Immunotherapy.

[18]  Galina Kurteva,et al.  Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. , 2013, The Lancet. Oncology.

[19]  Zhiyuan Hu,et al.  Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker , 2013, BMC Cancer.

[20]  F. Berthold,et al.  Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Ash A. Alizadeh,et al.  Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47 , 2010, Science Translational Medicine.

[22]  Ash A. Alizadeh,et al.  Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma , 2010, Cell.

[23]  I. Weissman,et al.  CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.

[24]  Manzoor Ahmad,et al.  Tuftsin Augments Antitumor Efficacy of Liposomized Etoposide against Fibrosarcoma in Swiss Albino Mice , 2007, Molecular medicine.

[25]  M. Fridkin,et al.  Tuftsin: its chemistry, biology, and clinical potential. , 1989, Critical reviews in biochemistry and molecular biology.